OTLK is trading 6.2% up today at $1.55 on follow-through positioning ahead of a July FDA action date for its wet-AMD drug, Lytenava.
- The move extends a mild rebound following recent weakness and a sharp surge in June when the FDA set the upcoming decision date.
- There are no fresh company-specific headlines this morning; today's gains appear driven by investor anticipation rather than new news.
- The stock previously jumped 28% in a single session after the regulatory catalyst was first announced.